期刊文献+

miRNA-451和钙结合蛋白39在非小细胞肺癌患者中的表达及临床意义

Expression and clinical significance of miRNA-451 and calcium binding protein 39 in non-small cell lung cancer patients
下载PDF
导出
摘要 目的探讨微小RNA(miRNA)-451和钙结合蛋白39(CAB39)在非小细胞肺癌(NSCLC)患者中的表达及临床意义。方法收集180例NSCLC患者的NSCLC组织和对应的癌旁组织,采用实时荧光定量聚合酶链反应检测miRNA-451相对表达量,采用免疫组织化学染色法检测CAB39表达情况。采用多因素Logistic回归模型分析NSCLC患者NSCLC组织中miRNA-451和CAB39表达情况的影响因素。比较不同miRNA-451、CAB39表达情况NSCLC患者的预后。结果NSCLC组织中miRNA-451相对表达量和CAB39阳性表达率均明显低于癌旁组织,差异均有统计学意义(P<0.01)。肿瘤直径>3 cm、有淋巴结转移、临床分期为Ⅲ~Ⅳ的NSCLC患者NSCLC组织中miRNA-451高表达率和CAB39阳性表达率均低于肿瘤直径≤3 cm、无淋巴结转移、临床分期为Ⅰ~Ⅱ期的患者,差异均有统计学意义(P<0.05)。多因素Logistic回归分析结果显示,淋巴结转移情况、临床分期均是NSCLC患者NSCLC组织中miRNA-451和CAB39表达情况的独立影响因素(P<0.05)。miRNA-451低表达患者的中位生存时间短于miRNA-451高表达患者,CAB39阴性表达患者的中位生存时间短于CAB39阳性表达患者,差异均有统计学意义(P<0.05)。结论NSCLC组织中miRNA-451和CAB39表达水平均明显低于癌旁组织,miRNA-451低表达和CAB39阴性表达可能会促进肿瘤生长、淋巴结转移,有望成为NSCLC患者治疗效果及预后的评估指标。 Objective To investigate the expression and clinical significance of microRNA(miRNA)-451 and calcium binding protein 39(CAB39)in patients with non-small cell lung cancer(NSCLC).Method The NSCLC tissues and corresponding paracancerous tissues from 180 NSCLC patients were collected.The relative expression of miRNA-451was detected by real-time fluorescence quantitative polymerase chain reaction.The expression of CAB39 was detected by immunohistochemical staining.Multivariate Logistic regression model was constructed to analyze the influencing factors for miRNA-451 and CAB39 expression in NSCLC tissues of NSCLC patients.The prognosis of NSCLC patients with different expression of miRNA-451 and CAB39 were also compared.Result The relative expression of miRNA-451 and the positive rate of CAB39 in NSCLC tissues were significantly lower than those in paracancerous tissues,and the differences were statistically significant(P<0.01).The high expression rate of miRNA-451 and the positive rate of CAB39 in NSCLC tissues of NSCLC patients with tumor diameter>3 cm,lymph node metastasis,and clinical stage Ⅲ-Ⅳ were lower than those with tumor diameter≤3 cm,no lymph node metastasis,and clinical stage Ⅰ-Ⅱ,and the differences were statistically significant(P<0.05).Multivariate Logistic regression analysis showed that lymph node metastasis and clinical stage were independent risk factors for miRNA-451 and CAB39 expression in NSCLC tissues of NSCLC patients(P<0.05).The median survival time of patients with miRNA-451 low-expression was shorter than that of the miRNA-451high-expression,and the median survival time of the patients with CAB39 negative expression was shorter than that of the CAB39 positive expression,and the differences were statistically significant(P<0.05).Conclusion The expression levels of miRNA-451 and CAB39 in NSCLC tissues were significantly lower than those in paracancerous tissues.Downregulation of miRNA-451 and CAB39 negative expression may promote tumor growth and lymph node metastasis,which is expected to be evaluation indicators for the effect and prognosis of NSCLC patients.
作者 程涛 李卫阳 马程远 CHENG Tao;LI Weiyang;MAChengyuan(Department of Respiratory and Critical Care Medicine,Nanyang First People’s Hospital,Nanyang 473000,He’nan,China)
出处 《癌症进展》 2022年第16期1715-1718,共4页 Oncology Progress
关键词 miRNA-451 钙结合蛋白39 非小细胞肺癌 临床意义 miRNA-451 calcium binding protein 39 non-small cell lung cancer clinical significance
  • 相关文献

参考文献14

二级参考文献92

  • 1宋萍,李坚,殷凯生.检测外周血表皮生长因子受体表达在诊断肺癌微转移中的临床意义[J].江苏大学学报(医学版),2005,15(5):398-400. 被引量:5
  • 2Hirayama H, Wang Z, Nishi K, et al. Effect of Desmodium styraeifolium-triterpenoid on calcium oxalate renal stones. Br J Urol, 1993,71 : 143-147.
  • 3Wu Q, Yang Z, Nie Y, et al. Multi-drug resistance in cancer chemotherapeuties: mechanisms and lab approaches [ J ]. Cancer Lett, 2014, 347(2) : 159 - 166.
  • 4Kathawa[a RJ, Gupta P, Ashby CR Jr, et al. The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade[J]. Drug Resist Updat, 2015, 18:1 -17.
  • 5Scheffer GL, Schroeijers AB, lzquierdo MA, et ah Lung resistance- related protein/major vault protein and vaults in multidrug-resistant caneer[JI. Curr Opin Oneol, 2000, 12(6): 550 -556.
  • 6Pi|ati P, Nitti D, Mocellin S. Cancer resistance to type [I topoi- somerase inhibilors[J]. Curr Med Chem, 2012, 19(23): 3900- 3906.
  • 7Risinger AL, Li J, Bennett MJ, et al. Taccalonolide binding to tubulin imparts microtubule stability and potent in vi~,o activity[ J 1. Cancer Res, 2013, 73(22) : 6780 -6792.
  • 8Kong D, Ma S, Liang B, et al. The differenl regulatory effects ofp53 status on multidrug resistance are determined by autophagy in ovarian cancer ceils [ J ]. Biomed Pharnmcother, 2012, 66 (4) : 271 - 278.
  • 9Thomas S, Quinn BA, Das SK, et al. Targeting the Bcl-2 family for cancer therapy[ J]. Expert Opin Ther Targets, 2013, 17(1 ) : 61 -75.
  • 10Lord C J, Ashworth A. Mechanisms of resistance to therapies targeting BRCA-mutant cancers[ J~. Nat Med, 2013, 19 (11): 1381 - 1388.

共引文献136

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部